Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $64.75.

Several research analysts have recently commented on NTLA shares. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a research note on Tuesday. Citigroup lowered their target price on shares of Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, May 10th. Wedbush reiterated a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. Finally, Canaccord Genuity Group raised their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Friday, February 23rd.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. bought a new position in shares of Intellia Therapeutics in the fourth quarter worth about $26,000. Signaturefd LLC grew its holdings in Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock valued at $49,000 after purchasing an additional 751 shares during the period. Daiwa Securities Group Inc. boosted its holdings in shares of Intellia Therapeutics by 35.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock valued at $93,000 after buying an additional 793 shares during the period. EntryPoint Capital LLC boosted its holdings in Intellia Therapeutics by 61.1% during the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after purchasing an additional 1,563 shares during the last quarter. Finally, Spire Wealth Management boosted its holdings in Intellia Therapeutics by 3,789.0% during the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock worth $119,000 after purchasing an additional 3,789 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

NTLA stock opened at $24.80 on Wednesday. Intellia Therapeutics has a 12 month low of $19.37 and a 12 month high of $46.50. The firm has a market cap of $2.39 billion, a PE ratio of -4.63 and a beta of 1.84. The firm has a 50 day simple moving average of $23.61 and a 200 day simple moving average of $26.60.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.29. The business had revenue of $28.94 million during the quarter, compared to the consensus estimate of $15.60 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. As a group, sell-side analysts expect that Intellia Therapeutics will post -4.98 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.